Vir Biotechnology Quarterly Income Statement
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vir Biotechnology revenue and earnings
In the quarter ended Jun 30, 2026, Vir Biotechnology generated $238.9 million in revenue, up 19582.5% from the same quarter a year earlier. Net income was $80.1 million, for a net margin of 33.5% versus a median of -3989.6% in the prior 5 quarters. Gross margin was 100.0% (up from 99.1%) and operating margin 30.7%.
Diluted earnings per share came in at $0.47.
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238.95M | -29.00K | 64.07M | 240.00K | 1.21M | 3.03M | 12.37M | 2.38M | 3.08M | 56.38M | 16.79M | 2.64M |
| Revenue growth (YoY) | +19582.54% | -100.96% | +417.78% | -89.92% | -60.52% | -94.62% | -26.29% | -9.81% | -19.02% | -10.45% | -66.03% | -99.30% |
| Cost of Revenue | 0 | — | — | — | 11.00K | 0 | 684.00K | 50.00K | 52.00K | 59.00K | 798.00K | 38.00K |
| Gross Profit | 238.95M | — | — | — | 1.20M | 3.03M | 11.69M | 2.33M | 3.02M | 56.32M | 15.99M | 2.60M |
| Operating Expenses | 165.48M | — | — | — | 119.62M | 142.58M | 128.84M | 233.63M | 161.65M | 136.40M | 155.00M | 189.33M |
| Research & Development | 135.28M | 108.92M | 88.35M | 151.46M | 97.51M | 118.64M | 106.08M | 195.18M | 105.11M | 100.13M | 108.97M | 145.03M |
| Selling, General & Admin | 30.20M | 23.34M | 23.62M | 22.23M | 22.28M | 23.94M | 26.70M | 25.74M | 30.27M | 36.32M | 41.22M | 40.93M |
| Operating Income | 73.47M | -132.29M | -47.92M | -173.44M | -118.42M | -139.55M | -117.15M | -231.30M | -158.63M | -80.08M | -139.02M | -186.73M |
| Other Income (Expense) | 6.79M | 6.76M | 4.86M | 10.47M | 7.63M | 18.60M | 12.47M | 17.76M | 18.74M | 15.08M | 18.26M | 20.11M |
| Pretax Income | 80.26M | -125.53M | -43.06M | -162.97M | -110.79M | -120.95M | -104.67M | -213.54M | -139.89M | -65.00M | -120.76M | -166.63M |
| Income Tax | 179.00K | 170.00K | -137.00K | 168.00K | 170.00K | 16.00K | -86.00K | 177.00K | -1.51M | 276.00K | -4.78M | -3.21M |
| Net Income | 80.08M | -125.69M | -42.92M | -163.14M | -110.96M | -120.97M | -104.59M | -213.72M | -138.38M | -65.28M | -115.97M | -163.41M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -193.21% |
| EPS (Basic) | 0.48 | -0.85 | -0.31 | -1.17 | -0.80 | -0.88 | -0.77 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 |
| EPS (Diluted) | 0.47 | -0.85 | -0.31 | -1.17 | -0.80 | -0.88 | -0.77 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 |
| Shares Outstanding (Basic) | 167.72M | 147.36M | — | 138.93M | 138.45M | 137.47M | — | 136.65M | 136.22M | 135.28M | — | 134.29M |
| Shares Outstanding (Diluted) | 168.88M | 147.36M | — | 138.93M | 138.45M | 137.47M | — | 136.65M | 136.22M | 135.28M | — | 134.29M |
| EBITDA | 76.27M | -129.48M | -45.02M | -170.44M | -115.50M | -136.68M | -114.26M | -228.41M | -154.37M | -75.56M | -134.54M | -182.23M |
| Gross Margin | 100.00% | — | — | — | 99.09% | 100.00% | 94.47% | 97.90% | 98.31% | 99.90% | 95.25% | 98.56% |
| Operating Margin | 30.75% | 456172.41% | -74.79% | -72267.92% | -9754.28% | -4602.47% | -946.74% | -9718.66% | -5158.70% | -142.05% | -828.12% | -7075.86% |
| Net Margin | 33.51% | 433431.03% | -66.99% | -67975.42% | -9139.87% | -3989.61% | -845.23% | -8979.71% | -4500.10% | -115.79% | -690.85% | -6192.23% |
This table shows 12 quarterly periods of Vir Biotechnology's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a income statement?